Published in J Natl Cancer Inst on January 02, 2002
DNA methylation profiling in the clinic: applications and challenges. Nat Rev Genet (2012) 3.33
Critical role of histone methylation in tumor suppressor gene silencing in colorectal cancer. Mol Cell Biol (2003) 2.72
Validation of real-time methylation-specific PCR to determine O6-methylguanine-DNA methyltransferase gene promoter methylation in glioma. J Mol Diagn (2008) 2.71
Methylation-sensitive high resolution melting (MS-HRM): a new approach for sensitive and high-throughput assessment of methylation. Nucleic Acids Res (2007) 2.69
Risk of non-Hodgkin lymphoma (NHL) in relation to germline variation in DNA repair and related genes. Blood (2006) 2.02
Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma. Cancer Discov (2013) 1.90
Aberrant CpG island hypermethylation of chronic gastritis, in relation to aging, gender, intestinal metaplasia, and chronic inflammation. Am J Pathol (2003) 1.79
Epigenetics as a mechanism driving polygenic clinical drug resistance. Br J Cancer (2006) 1.77
Frequent promoter methylation of CDH1, DAPK, RARB, and HIC1 genes in carcinoma of cervix uteri: its relationship to clinical outcome. Mol Cancer (2003) 1.73
DNA methylation profiles in diffuse large B-cell lymphoma and their relationship to gene expression status. Leukemia (2008) 1.70
Variability in DNA methylation defines novel epigenetic subgroups of DLBCL associated with different clinical outcomes. Blood (2014) 1.64
Epigenetic regulation of CD44 in Hodgkin and non-Hodgkin lymphoma. BMC Cancer (2010) 1.55
DUSP4 deficiency caused by promoter hypermethylation drives JNK signaling and tumor cell survival in diffuse large B cell lymphoma. J Exp Med (2015) 1.48
Canadian recommendations for the treatment of glioblastoma multiforme. Curr Oncol (2007) 1.24
Integrating Epigenomics into Pharmacogenomic Studies. Pharmgenomics Pers Med (2008) 1.18
MGMT promoter methylation, loss of expression and prognosis in 855 colorectal cancers. Cancer Causes Control (2010) 1.16
Characteristic promoter hypermethylation signatures in male germ cell tumors. Mol Cancer (2002) 1.13
DNA methylation biomarkers: cancer and beyond. Genes (Basel) (2014) 1.11
Canadian recommendations for the treatment of recurrent or progressive glioblastoma multiforme. Curr Oncol (2011) 1.06
Role of promoter hypermethylation in Cisplatin treatment response of male germ cell tumors. Mol Cancer (2004) 1.04
Global DNA methylation profiling reveals silencing of a secreted form of Epha7 in mouse and human germinal center B-cell lymphomas. Oncogene (2007) 1.02
Investigation of MGMT and DAPK1 methylation patterns in diffuse large B-cell lymphoma using allelic MSP-pyrosequencing. Sci Rep (2013) 0.94
CpG methylation analysis--current status of clinical assays and potential applications in molecular diagnostics: a report of the Association for Molecular Pathology. J Mol Diagn (2009) 0.94
Aberrant methylation of p16 predicts candidates for 5-fluorouracil-based adjuvant therapy in gastric cancer patients. J Gastroenterol (2007) 0.94
Genome-wide epigenetic modifications in cancer. Prog Drug Res (2011) 0.93
Use of cell lines in the investigation of pharmacogenetic loci. Curr Pharm Des (2009) 0.93
Frequent and simultaneous epigenetic inactivation of TP53 pathway genes in acute lymphoblastic leukemia. PLoS One (2011) 0.93
Role of MGMT in protecting against cyclophosphamide-induced toxicity in cells and animals. DNA Repair (Amst) (2007) 0.88
Role of gene methylation in antitumor immune response: implication for tumor progression. Cancers (Basel) (2011) 0.87
The B cell transcription program mediates hypomethylation and overexpression of key genes in Epstein-Barr virus-associated proliferative conversion. Genome Biol (2013) 0.85
Methylation profiles of CpG island loci in major types of human cancers. J Korean Med Sci (2007) 0.84
Colorectal cancer DNA methylation marker panel validated with high performance in Non-Hodgkin lymphoma. Epigenetics (2013) 0.83
Altered expression of MGMT in high-grade gliomas results from the combined effect of epigenetic and genetic aberrations. PLoS One (2013) 0.83
The role of gene body cytosine modifications in MGMT expression and sensitivity to temozolomide. Mol Cancer Ther (2014) 0.83
Clinical implications of promoter hypermethylation in RASSF1A and MGMT in retinoblastoma. Neoplasia (2005) 0.82
The clinical value of aberrant epigenetic changes of DNA damage repair genes in human cancer. Oncotarget (2016) 0.81
Primary follicular lymphoma of the testis in childhood: an entity with peculiar clinical and molecular characteristics. J Clin Pathol (2002) 0.79
Identification of highly methylated genes across various types of B-cell non-hodgkin lymphoma. PLoS One (2013) 0.77
A gene panel, including LRP12, is frequently hypermethylated in major types of B-cell lymphoma. PLoS One (2014) 0.77
SNP rs16906252C>T Is an Expression and Methylation Quantitative Trait Locus Associated with an Increased Risk of Developing MGMT-Methylated Colorectal Cancer. Clin Cancer Res (2016) 0.76
Genetic and epigenetic markers to identify high risk patients for multiple early gastric cancers after treatment with endoscopic mucosal resection. J Clin Biochem Nutr (2007) 0.76
Survival and tumorigenesis in O6-methylguanine DNA methyltransferase-deficient mice following cyclophosphamide exposure. Mutagenesis (2008) 0.76
Epigenetic changes mediated by polycomb repressive complex 2 and E2a are associated with drug resistance in a mouse model of lymphoma. Genome Med (2016) 0.75
Silence is golden: gene hypermethylation and survival in large-cell lymphoma. J Natl Cancer Inst (2002) 0.75
Expression of O(6)-methylguanine-DNA methyltransferase causes lomustine resistance in canine lymphoma cells. Can J Vet Res (2015) 0.75
Diagnostic and predictive biomarkers for lymphoma diagnosis and treatment in the era of precision medicine. Mod Pathol (2016) 0.75
The epigenomics of cancer. Cell (2007) 30.91
The fundamental role of epigenetic events in cancer. Nat Rev Genet (2002) 30.05
Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med (2013) 19.87
Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med (2003) 18.04
Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell (2010) 16.12
A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. Nat Genet (2007) 9.47
DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature (2002) 9.40
Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat Genet (2004) 7.78
Follicular lymphoma international prognostic index. Blood (2004) 7.20
Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung. Cancer Res (2002) 7.09
Hedgehog signalling within airway epithelial progenitors and in small-cell lung cancer. Nature (2003) 6.07
Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet (2011) 6.06
Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci U S A (2005) 5.91
DNA methylation markers and early recurrence in stage I lung cancer. N Engl J Med (2008) 5.87
Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer. PLoS Med (2006) 5.80
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med (2015) 5.71
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. N Engl J Med (2015) 5.69
A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat Genet (2002) 5.38
An ethics framework for a learning health care system: a departure from traditional research ethics and clinical ethics. Hastings Cent Rep (2013) 5.27
Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature (2011) 5.20
Tumor suppressor HIC1 directly regulates SIRT1 to modulate p53-dependent DNA-damage responses. Cell (2005) 5.04
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med (2014) 4.81
Lung cancer screening with helical computed tomography in older adult smokers: a decision and cost-effectiveness analysis. JAMA (2003) 4.81
The research-treatment distinction: a problematic approach for determining which activities should have ethical oversight. Hastings Cent Rep (2013) 4.69
Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov (2011) 4.60
ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned. N Engl J Med (2011) 4.50
Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. J Exp Med (2011) 4.37
Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol (2008) 4.32
Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res (2006) 4.15
Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol (2007) 3.99
Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer Cell (2012) 3.82
Short double-stranded RNA induces transcriptional gene silencing in human cancer cells in the absence of DNA methylation. Nat Genet (2005) 3.66
Rethinking randomized clinical trials for comparative effectiveness research: the need for transformational change. Ann Intern Med (2009) 3.60
Silenced tumor suppressor genes reactivated by DNA demethylation do not return to a fully euchromatic chromatin state. Cancer Res (2006) 3.59
R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. J Clin Oncol (2013) 3.58
Inhibition of SIRT1 reactivates silenced cancer genes without loss of promoter DNA hypermethylation. PLoS Genet (2006) 3.54
Butyrate greatly enhances derivation of human induced pluripotent stem cells by promoting epigenetic remodeling and the expression of pluripotency-associated genes. Stem Cells (2010) 3.53
Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology Study. J Clin Oncol (2002) 3.53
The cancer epigenome--components and functional correlates. Genes Dev (2006) 3.40
Comparing the DNA hypermethylome with gene mutations in human colorectal cancer. PLoS Genet (2007) 3.39
Systematic review: gene expression profiling assays in early-stage breast cancer. Ann Intern Med (2008) 3.32
Random-effects meta-analysis of inconsistent effects: a time for change. Ann Intern Med (2014) 3.30
A blinded, crossover study of the efficacy of the ketogenic diet. Epilepsia (2008) 3.28
Cardiac resynchronization and death from progressive heart failure: a meta-analysis of randomized controlled trials. JAMA (2003) 3.25
EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues. Am J Pathol (2009) 3.15
Reproducible research: moving toward research the public can really trust. Ann Intern Med (2007) 3.10
Oxidative damage targets complexes containing DNA methyltransferases, SIRT1, and polycomb members to promoter CpG Islands. Cancer Cell (2011) 3.07
Promoter hypermethylation of multiple genes in sputum precedes lung cancer incidence in a high-risk cohort. Cancer Res (2006) 3.05
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med (2015) 3.00
Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumours. J Pathol (2002) 3.00
Low-level microsatellite instability in most colorectal carcinomas. Cancer Res (2002) 2.87
PcG proteins, DNA methylation, and gene repression by chromatin looping. PLoS Biol (2008) 2.85
Dependence of histone modifications and gene expression on DNA hypermethylation in cancer. Cancer Res (2002) 2.84
Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood (2010) 2.84
A systematic profile of DNA methylation in human cancer cell lines. Cancer Res (2003) 2.75
Prognostic impact of monocyte count at presentation in mantle cell lymphoma. Br J Haematol (2013) 2.66
Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer's disease: a systematic review. Neuroepidemiology (2004) 2.63
Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. Blood (2012) 2.58
Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood (2003) 2.56
Stem cell chromatin patterns: an instructive mechanism for DNA hypermethylation? Cell Cycle (2007) 2.55
Double strand breaks can initiate gene silencing and SIRT1-dependent onset of DNA methylation in an exogenous promoter CpG island. PLoS Genet (2008) 2.55
Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia. Blood (2014) 2.53
Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer. J Clin Oncol (2012) 2.53
The mammography dilemma: a crisis for evidence-based medicine? Ann Intern Med (2002) 2.49
RNAi-mediated silencing of nuclear factor erythroid-2-related factor 2 gene expression in non-small cell lung cancer inhibits tumor growth and increases efficacy of chemotherapy. Cancer Res (2008) 2.45
Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness. Blood (2011) 2.44
Aberrant promoter methylation profiles of tumor suppressor genes in hepatocellular carcinoma. Am J Pathol (2003) 2.42
GATA-4 and GATA-5 transcription factor genes and potential downstream antitumor target genes are epigenetically silenced in colorectal and gastric cancer. Mol Cell Biol (2003) 2.42
Hematopoietic stem cells convert into liver cells within days without fusion. Nat Cell Biol (2004) 2.41
Histone modifications and silencing prior to DNA methylation of a tumor suppressor gene. Cancer Cell (2003) 2.38
Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients. Blood (2011) 2.37
The NF-{kappa}B negative regulator TNFAIP3 (A20) is inactivated by somatic mutations and genomic deletions in marginal zone lymphomas. Blood (2009) 2.36
SOCS-1, a negative regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma. Blood (2002) 2.34
Sensitive digital quantification of DNA methylation in clinical samples. Nat Biotechnol (2009) 2.34
Breast cancer methylomes establish an epigenomic foundation for metastasis. Sci Transl Med (2011) 2.33
Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol (2008) 2.32
Prognostic importance of promoter hypermethylation of multiple genes in esophageal adenocarcinoma. Clin Cancer Res (2003) 2.28